Mechanism of glucose‐lowering by metformin in type 2 diabetes: Role of bile acids

Important Role of the GLP-1 Axis for Glucose Homeostasis after Bariatric Surgery

(2019) Pierre Larraufie et al.   Cell Reports

Metformin-induced changes of the gut microbiota in healthy young men: results of a non-blinded, one-armed intervention study

(2019) Thomas Bryrup et al.   DIABETOLOGIA

Effect of Roux-en-Y gastric bypass surgery on diabetes remission and complications in individuals with type 2 diabetes: a Danish population-based matched cohort study

(2019) Lene R. Madsen et al.   DIABETOLOGIA

Gastric emptying in patients with well-controlled type 2 diabetes compared to non-diabetic young and older controls

(2019) Linda E Watson et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Intestine farnesoid X receptor agonist and the gut microbiota activate G-protein bile acid receptor-1 signaling to improve metabolism

(2018) Preeti Pathak et al.   HEPATOLOGY

Bile acids are important direct and indirect regulators of the secretion of appetite- and metabolism-regulating hormones from the gut and pancreas

(2018) Rune E. Kuhre et al.   Molecular Metabolism

Intestinal bitter taste receptor activation alters hormone secretion and imparts metabolic benefits

(2018) Bernard P. Kok et al.   Molecular Metabolism

9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2019

(2018)   DIABETES CARE

Comparative effects of proximal and distal small intestinal administration of metformin on plasma glucose and glucagon-like peptide-1, and gastric emptying after oral glucose, in type 2 diabetes

(2018) Malcolm J. Borg et al.   DIABETES OBESITY & METABOLISM

Role of Bile Acids and GLP-1 in Mediating the Metabolic Improvements of Bariatric Surgery

(2018) Vance L. Albaugh et al.   GASTROENTEROLOGY

Gut microbiota and intestinal FXR mediate the clinical benefits of metformin

(2018) Lulu Sun et al.   NATURE MEDICINE

Single-Dose Metformin Enhances Bile Acid–Induced Glucagon-Like Peptide-1 Secretion in Patients With Type 2 Diabetes

(2017) Andreas Brønden et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Bile acid sequestrants for glycemic control in patients with type 2 diabetes: A systematic review with meta-analysis of randomized controlled trials

(2017) Morten Hansen et al.   JOURNAL OF DIABETES AND ITS COMPLICATIONS

Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug

(2017) Hao Wu et al.   NATURE MEDICINE

Effect of chenodeoxycholic acid and the bile acid sequestrant colesevelam on glucagon-like peptide-1 secretion

(2016) M. Hansen et al.   DIABETES OBESITY & METABOLISM

Sustained influence of metformin therapy on circulating glucagon-like peptide-1 levels in individuals with and without type 2 diabetes

(2016) David Preiss et al.   DIABETES OBESITY & METABOLISM

Once-daily delayed-release metformin lowers plasma glucose and enhances fasting and postprandial GLP-1 and PYY: results from two randomised trials

(2016) Ralph A. DeFronzo et al.   DIABETOLOGIA

Cholecystokinin-Induced Gallbladder Emptying and Metformin Elicit Additive Glucagon-Like Peptide-1 Responses

(2016) Ulrich Rohde et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

New insights into the anti-diabetic actions of metformin: from the liver to the gut

(2016) Tongzhi Wu et al.   Expert Review of Gastroenterology & Hepatology

Inhibition of the multidrug and toxin extrusion (MATE) transporter by pyrimethamine increases the plasma concentration of metformin but does not increase antihyperglycaemic activity in humans

(2015) J. Oh et al.   DIABETES OBESITY & METABOLISM

Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota

(2015) Kristoffer Forslund et al.   NATURE

Metformin activates a duodenal Ampk–dependent pathway to lower hepatic glucose production in rats

(2015) Frank A Duca et al.   NATURE MEDICINE

Farnesoid X receptor inhibits glucagon-like peptide-1 production by enteroendocrine L cells

(2015) Mohamed-Sami Trabelsi et al.   Nature Communications

Bile diversion to the distal small intestine has comparable metabolic benefits to bariatric surgery

(2015) Charles Robb Flynn et al.   Nature Communications

Mechanism of increase in plasma intact GLP-1 by metformin in type 2 diabetes: Stimulation of GLP-1 secretion or reduction in plasma DPP-4 activity?

(2014) Tongzhi Wu et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Denatonium induces secretion of glucagon-like peptide-1 through activation of bitter taste receptor pathways

(2014) Ki-Suk Kim et al.   DIABETOLOGIA

Metformin in Patients With Type 2 Diabetes and Kidney Disease

(2014) Silvio E. Inzucchi et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Novel Gut-Based Pharmacology of Metformin in Patients with Type 2 Diabetes Mellitus

(2014) Antonella Napolitano et al.   PLoS One

Gut Microbiota Regulates Bile Acid Metabolism by Reducing the Levels of Tauro-beta-muricholic Acid, a Naturally Occurring FXR Antagonist

(2013) Sama I. Sayin et al.   Cell Metabolism

Mechanisms of Glucose Lowering of Dipeptidyl Peptidase-4 Inhibitor Sitagliptin When Used Alone or With Metformin in Type 2 Diabetes

(2013) Carolina Solis-Herrera et al.   DIABETES CARE

Effects of Taurocholic Acid on Glycemic, Glucagon-like Peptide-1, and Insulin Responses to Small Intestinal Glucose Infusion in Healthy Humans

(2013) Tongzhi Wu et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Metformin enhances glucagon-like peptide 1 via cooperation between insulin and Wnt signaling

(2013) Mi-Hyun Kim et al.   JOURNAL OF ENDOCRINOLOGY

Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity

(2013) Fei Li et al.   Nature Communications

Long-Term Safety, Tolerability, and Weight Loss Associated With Metformin in the Diabetes Prevention Program Outcomes Study

(2012)   DIABETES CARE

Effects of rectal administration of taurocholic acid on glucagon-like peptide-1 and peptide YY secretion in healthy humans

(2012) T. Wu et al.   DIABETES OBESITY & METABOLISM

Effects of chronic treatment with metformin on dipeptidyl peptidase-4 activity, glucagon-like peptide 1 and ghrelin in obese patients with Type 2 diabetes mellitus

(2012) S. K. Thondam et al.   DIABETIC MEDICINE

Rectal taurocholate increases L cell and insulin secretion, and decreases blood glucose and food intake in obese type 2 diabetic volunteers

(2012) T. E. Adrian et al.   DIABETOLOGIA

Direct effect of GLP-1 infusion on endogenous glucose production in humans

(2012) M. Seghieri et al.   DIABETOLOGIA

A metagenome-wide association study of gut microbiota in type 2 diabetes

(2012) Junjie Qin et al.   NATURE

Mechanisms Underlying Metformin-Induced Secretion of Glucagon-Like Peptide-1 from the Intestinal L Cell

(2011) Andrew J. Mulherin et al.   ENDOCRINOLOGY

Metformin and Cancer Risk in Diabetic Patients: A Systematic Review and Meta-analysis

(2010) A. DeCensi et al.   Cancer Prevention Research

Dipeptidyl Peptidase-4 Inhibitors Administered in Combination With Metformin Result in an Additive Increase in the Plasma Concentration of Active GLP-1

(2010) E M Migoya et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Gut Microbiota in Health and Disease

(2010) Inna Sekirov et al.   PHYSIOLOGICAL REVIEWS

TGR5-Mediated Bile Acid Sensing Controls Glucose Homeostasis

(2009) Charles Thomas et al.   Cell Metabolism

Reduced-Function SLC22A1 Polymorphisms Encoding Organic Cation Transporter 1 and Glycemic Response to Metformin: A GoDARTS Study

(2009) K. Zhou et al.   DIABETES

Bitter Taste Receptors Influence Glucose Homeostasis

(2008) Cedrick D. Dotson et al.   PLoS One